- Telehealth visits
Kensho Iwanaga, MD, MS
Pediatric Pulmonology • Pediatric Sleep MedicineKensho Iwanaga, MD, MS
Pediatric Pulmonology • Pediatric Sleep Medicine- Telehealth visits
On this page
About me
Dr. Kensho Iwanaga is a specialist in pediatric pulmonology who cares for infants, children and adolescents with acute and chronic respiratory conditions, including asthma, cystic fibrosis and bronchopulmonary dysplasia (a lung condition most common in premature newborns that can lead to chronic breathing problems).
Iwanaga's research focuses on understanding the interactions between air pollution and pediatric respiratory health and development.
Iwanaga is a Bay Area native. He completed his undergraduate studies at the University of California, Berkeley and earned his medical degree at the University of California, Irvine. He completed a residency in pediatrics at UCSF Benioff Children's Hospital Oakland, followed by a fellowship in pediatric pulmonology at Seattle Children's Hospital. During his fellowship, he earned a master's degree in epidemiology from the University of Washington School of Public Health.
Education & training
Board certification
- Pediatric Pulmonology, American Board of Pediatrics
Fellowship
- Pulmonary Disease, Seattle Childrens Hospital and Medical Center
Residency
- UCSF Benioff Children's Hospital--Oakland
- Pediatrics, Childrens Hospital and Medical Center - GME
Internship
- Pediatrics, Childrens Hospital and Medical Center - GME
Degree
- MD, University of California Irvine College of Medicine
Academic Title
- Health Sciences Clinical Professor
My expertise
Locations
My research
Publications
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.
The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.